Hospital for Special SurgeryNew York
Abaloparatide(Hospital for Special Surgery, New York)은 Osteoporosis, Postmenopausal 표적 치료제로, Osteoporosis, Postmenopausal 영역에서 개발·상용화 중입니다. 작용기전: , efficacy, safety, and relevance for patients with low bone turnover and high fracture risk. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 0.031% (ClinicalTrials.gov NCT04366726). 차별점: novel mode of administration, the abaloparatide-solid Microstructured Transdermal System (abaloparatide-sMTS), which is appli.
Osteoporosis, Postmenopausal
Osteoporosis, Postmenopausal
Recruiting
gene therapy, and mesenchymal stem cell transplantation, fall within thi
novel mode of administration, the abaloparatide-solid Microstructured Transdermal System (abaloparatide-sMTS), which is appli
, efficacy, safety, and relevance for patients with low bone turnover and high fracture risk
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Hospital for Special SurgeryNew York
Abaloparatide(Hospital for Special Surgery, New York)은 Osteoporosis, Postmenopausal 표적 치료제로, Osteoporosis, Postmenopausal 영역에서 개발·상용화 중입니다. 작용기전: , efficacy, safety, and relevance for patients with low bone turnover and high fracture risk. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 0.031% (ClinicalTrials.gov NCT04366726). 차별점: novel mode of administration, the abaloparatide-solid Microstructured Transdermal System (abaloparatide-sMTS), which is appli.
Osteoporosis, Postmenopausal
Osteoporosis, Postmenopausal
Recruiting
gene therapy, and mesenchymal stem cell transplantation, fall within thi
novel mode of administration, the abaloparatide-solid Microstructured Transdermal System (abaloparatide-sMTS), which is appli
, efficacy, safety, and relevance for patients with low bone turnover and high fracture risk
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.